Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

A chemical used in BPA-free products may have a connection to diabetes control

23

Sep 2026

A chemical used in BPA-free products may have a connection to diabetes control

In adults with type 2 diabetes receiving oral glucose-lowering therapy, higher plasma BPS concentrations were associated with higher HbA1c after accounting for demographic factors, medication adherence, and diet, whereas BPA was not associated with HbA1c. The BPS association was modest and no longer statistically significant after further adjustment for BPA, BMI, and physical fitness, supporting the need for larger studies to determine whether reducing exposure could improve glycemic control.

Screening approved medicines reveals potential treatments for preterm labor

23

Sep 2026

Screening approved medicines reveals potential treatments for preterm labor

Shajila Siricilla, PhD, Assistant Professor of Pediatrics, and Jennifer Herington, PhD, Associate Professor of Pediatrics, led a team that systematically screened 1,191 FDA-approved drugs and found that several candidates met criteria supporting further evaluation as potential treatments for preterm labor.

Slow-growing progenitor cells cause smooth brains in common marmosets

23

Sep 2026

Slow-growing progenitor cells cause smooth brains in common marmosets

Most primate species have a relatively large brain with a surface marked by pronounced bulges and furrows. This is not the case with common marmosets (Callithrix jacchus). The brains of these small monkeys are smooth and virtually unfolded.

Experimental drug reverses multiple sclerosis damage in mouse model

23

Sep 2026

Experimental drug reverses multiple sclerosis damage in mouse model

A drug developed by a UVA Health scientist has not only stopped but reversed paralysis and vision loss in a mouse model of multiple sclerosis.

Experimental drug reverses multiple sclerosis damage in mouse model

23

Sep 2026

Experimental drug reverses multiple sclerosis damage in mouse model

A drug developed by a UVA Health scientist has not only stopped but reversed paralysis and vision loss in a mouse model of multiple sclerosis.

Experimental drug reverses multiple sclerosis damage in mouse model

23

Sep 2026

Experimental drug reverses multiple sclerosis damage in mouse model

A drug developed by a UVA Health scientist has not only stopped but reversed paralysis and vision loss in a mouse model of multiple sclerosis.

New AI tool detects signs of endometriosis in milliseconds

23

Sep 2026

New AI tool detects signs of endometriosis in milliseconds

Less than a second. That's how long it takes for an emerging AI tool to detect signs of endometriosis through one simple scan.

New 3D lipid atlas maps the chemistry of mouse brains

23

Sep 2026

New 3D lipid atlas maps the chemistry of mouse brains

The brain is often described in terms of cells and wiring. However, much of it is made of lipids that form the membranes of neurons, wrap nerve fibers with myelin, and help brain cells send and receive signals.

Discovery of receptor-free signaling reveals better targets for treating autoimmune diseases

23

Sep 2026

Discovery of receptor-free signaling reveals better targets for treating autoimmune diseases

Our understanding of how cells interact with each other has been driven for decades by the central concept of receptor-mediated signal transduction.

Brain organoids reveal new clues for childhood epilepsy treatments

23

Sep 2026

Brain organoids reveal new clues for childhood epilepsy treatments

Tiny, year-old human brain organoids that mimic the brain of a newborn are providing new clues to potential treatments for a leading genetic cause of childhood epilepsy that typically manifests as the brain matures shortly after birth.

Prev

Page 7 of 16073

Next

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Mercury Pharmaceuticals

Mercury Pharmaceuticals

Why Us?

KNOWLEDGE OF RESEARCH ENVIRONMENT

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.

UNDERSTANDING INDUSTRIAL NEEDS

Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.

FOCUSED PROJECT MANAGEMENT

Smart approach to project management that helps speed up development stages and decision making.

INVESTMENT CAPABILITY

Availability of own investment up to 2m€ per project allows us to reach the next value milestone.